Bibiliografía

1. Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002 Nov 15;100(10):3484-8. [PubMed]

2. Monreal M, Falgá C, Valdés M, Suárez C, Gabriel F, Tolosa C, Montes J; Riete Investigators. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J Thromb Haemost. 2006 Sep;4(9):1950-6. [PubMed]

3. Van der Hulle T, den Exter PL, van den Hoven P, van der Hoeven JJ, van der Meer FJ, Eikenboom J, et al. Cohort Study on the Management of Cancer-Associated Venous Thromboembolism Aimed at the Safety of Stopping Anticoagulant Therapy in Patients Cured of Cancer. Chest. 2016 May;149(5):1245-51. [PubMed]

4. Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, et al.; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022 Jul;23(7):e334-e347. [PubMed]

5. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al.; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003 Jul 10;349(2):146-53. [PubMed]

6. Lee AY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, Khorana AA; CATCH Investigators. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. JAMA. 2015 Aug 18;314(7):677-86. [PubMed]

7. Pina E, Antonio M, Peris J, Rosselló E, Domènech P, Peñafiel J, Tebe C. Bemiparin as a long-term treatment for venous thrombosis in cancer patients: the ELEBAMA study. Clin Transl Oncol. 2020 Apr;22(4):616-620. [PubMed]

8. Raskob GE, Van Es N, Verhamme P, Carrier M, Di Nisio M, García D, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018 Feb 15;378(7):615-6124. [PubMed]

9. Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (Select-D). J Clin Oncol. 2018 Jul 10; 36(20):2017-2023. [PubMed]

10. Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM, et al; Caravaggio Investigators. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med. 2020 Apr 23;382(17):1599-607. [PubMed]

11. Trujillo-Santos J, Nieto JA, Tiberio G, Piccioli A, Di Micco P, Prandoni P, Monreal M; RIETE Registry. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost. 2008 Sep;100(3):435-9. [PubMed]

12. Mahé I, Chidiac J, Bertoletti L, Font C, Trujillo-Santos J, Peris M, et al.; RIETE investigators. The Clinical Course of Venous Thromboembolism May Differ According to Cancer Site. Am J Med. 2017 Mar;130(3):337-347. [PubMed]

13. McBane Ii RD, Vlazny DT, Houghton D, Casanegra AI, Froehling D, Daniels P, et al. Survival Implications of Thrombus Recurrence or Bleeding in Cancer Patients Receiving Anticoagulation for Venous Thromboembolism Treatment. Thromb Haemost. 2023 May;123(5):535-44. [PubMed]

14. Wysokinski WE, Houghton DE, Vlazny DT, Ashrani AA, Froehling DA, Kamath PS, et al. Influence of primary cancer site on clinical outcomes of anticoagulation for associated venous thromboembolism. Thromb Res. 2023 Jan;221:37-44. [PubMed]

15. Mulder FI, van Es N, Kraaijpoel N, Di Nisio M, Carrier M, Duggal A, et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study. Thromb Res. 2020 Jan;185:13-9. Erratum in: Thromb Res. 2020 Jul;191:156-9. [PubMed]

16. Verso M, Agnelli G, Muñoz A, Connors JM, Sánchez O, Huisman M, et al. Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study. Eur J Cancer. 2022 Apr;165:136-15. [PubMed]

17. Louzada ML, Carrier M, Lazo-Langner A, Dao V, Kovacs MJ, Ramsay TO, et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Circulation. 2012 Jul 24;126(4):448-54. [PubMed]

18. Astruc N, Ianotto JC, Metges JP, Lacut K, Delluc A. External validation of the modified Ottawa score for risk stratification of recurrent cancer-associated thrombosis.Eur J Intern Med. 2016 Dec;36:e11-e12. [PubMed]

19. Alatri A, Mazzolai L, Font C, Tafur A, Valle R, Marchena PJ, et al.; RIETE Investigators. Low discriminating power of the modified Ottawa VTE risk score in a cohort of patients with cancer from the RIETE registry.Thromb Haemost. 2017 Jul 26;117(8):1630-1636. [PubMed]

20. Girard P, Laporte S, Chapelle C, Falvo N, Falchero L, Cloarec N, et al. Failure of the Ottawa Score to Predict the Risk of Recurrent Venous Thromboembolism in Cancer Patients: The Prospective PREDICARE Cohort Study. Thromb Haemost. 2022 Jan;122(1):151-7. [PubMed]

21. Delluc A, Miranda S, Exter PD, Louzada M, Alatri A, Ahn S, et al. Accuracy of the Ottawa score in risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism: a systematic review and meta-analysis. Haematologica. 2020 May;105(5):1436-42. [PubMed]

22. Tafur AJ, Caprini JA, Cote L, Trujillo-Santos J, Del Toro J, Garcia-Bragado F, et al.; RIETE Investigators. Predictors of active cancer thromboembolic outcomes. RIETE experience of the Khorana score in cancer-associated thrombosis.Thromb Haemost. 2017 Jun 2;117(6):1192-1198. [PubMed]

23. Khorana AA, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, Lee AY. Tissue Factor As a Predictor of Recurrent Venous Thromboembolism in Malignancy: Biomarker Analyses of the CATCH Trial.J Clin Oncol. 2017 Apr 1;35(10):1078-1085. [PubMed]

24. Bauersachs R, Lee AYY, Kamphuisen PW, Meyer G, Janas MS, Jarner MF, Khorana AA; CATCH Investigators. Renal impairment, recurrent venous thromboembolism and bleeding in cancer patients with acute venous thromboembolism - Analysis of the CATCH Study. Thromb Haemost. 2018 May; 118(5):914-921. [PubMed]

25. Van Es N, Louzada M, Carrier M, Tagalakis V, Gross PL, Shivakumar S, Rodger MA, Wells PS. Predicting the risk of recurrent venous thromboembolism in patients with cancer: a prospective cohort study. Thromb Res. 2018 Mar;163:41-46. [PubMed]

26. Muñoz AJ, Huerga S, Souto JC, Rogado J, Sánchez A, García-Palomo A, et al. Predicting recurrence of venous thromboembolism in anticoagulated cancer patients using real-world data and machine learning. J Clin Oncol. 2022;40(16_suppl):e18742-e18742. Disponible en: [Enlace]

27. Schulman S. How I treat recurrent venous thromboembolism in patients on anticoagulant therapy.Blood. 2017 Jun 22; 129(25):3285-3293. [PubMed]

28. Carrier M, Le Gal G, Cho R, Tierney S, Rodger M, Lee AY. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients.J Thromb Haemost. 2009 May;7(5):760-5. [PubMed]

29. Schulman S, Zondag M, Linkins L, Pasca S, Cheung YW, de Sancho M, et al. Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis.J Thromb Haemost. 2015 Jun;13(6):1010-8. [PubMed]

30. Muriel A, Jiménez D, Aujesky D, Bertoletti L, Decousus H, Laporte S, Mismetti et al.; RIETE Investigators. Survival effects of inferior vena cava filter in patients with acute symptomatic venous thromboembolism and a significant bleeding risk.J Am Coll Cardiol. 2014 Apr 29;63(16):1675-83. [PubMed]

31. White RH, Brunson A, Romano PS, Li Z, Wun T. Outcomes After Vena Cava Filter Use in Noncancer Patients With Acute Venous Thromboembolism: A Population-Based Study.Circulation. 2016 May 24;133(21):2018-29. [PubMed]

32. Mellado M, Pijoan JI, Jiménez D, Muriel A, Aujesky D, Bertoletti L, et al.; RIETE Investigators. Outcomes Associated With Inferior Vena Cava Filters Among Patients With Thromboembolic Recurrence During Anticoagulant Therapy.JACC Cardiovasc Interv. 2016 Dec 12;9(23):2440-2448. [PubMed]

33. Carrier M, Khorana AA, Zwicker J, Noble S, Lee AY; Subcommittee on Haemostasis and Malignancy for the SSC of the ISTH. Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH.J Thromb Haemost. 2013 Sep;11(9):1760-5. [PubMed]

34. Piran S, Schulman S. Management of recurrent venous thrombosis in patients with cancer: a review. Thromb Res. 2018 Apr;164 Suppl 1:S172-S177. [PubMed]

35. Muñoz Martín AJ, Gallardo Díaz E, García Escobar I, Macías Montero R, Martínez-Marín V, Pachón Olmos V, et al. SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019). Clin Transl Oncol. 2020 Feb;22(2):171-86. [PubMed]